Drug Trial Radar · NCT06638502
Safety of HRX215 in Patients After Minor and Major Liver Resection
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
Jul 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- HepaRegeniX GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of HRX215 2. to learn about how the body absorbs, distributes, and gets rid of HRX215. 3. to learn about clinical activity of HRX215 Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.
Conditions
- Liver Resection
- Colorectal Carcinoma Liver Metastases
Interventions
HRX215 capsulesDrug
HRX215 250 mg orally twice daily for a total treatment duration of 28 days
Placebo capsulesDrug
placebo matching appearance of HRX215, orally twice daily for a total treatment duration of 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs) observedTime frame: 6 months
- HRX215 plasma levelsTime frame: 28 days
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Centre Hospitalier Régional Universitaire de Lille (CHRU) Hôpital Claude Huriez
Lille, France · Recruiting
Hôpital Paul-Brousse - Centre Hepato-Biliaire (CHB)
Villejuif, France · Recruiting
Universitatsklinikum Essen
Essen, Germany · Recruiting
Univ. Tuebingen - Universitaetsklinik fuer Allgemeine, Viszeral- und Transplantationschirurgie
Tübingen, Germany · Recruiting
Rabin Medical Center
Petah Tikva, Israel · Recruiting
Sheba Medical Center
Ramat Gan, Israel · Recruiting
Tel-Aviv Sourasky MC
Tel Aviv, Israel · Active not recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro
Madrid, Spain · Recruiting
Consorci Hospital General Universitari de València
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.